GUD · Knight Therapeutics Inc. · Investor Relations

MONTREAL, June 17, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has repaid all amounts outstanding under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The Credit Facility provides borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. In June 2025, Knight drew $60 million from the Credit Facility to support the acquisition of Paladin. The Company has repaid all outstanding amounts under the Credit Facility. “Today marks the one-year anniversary of the Paladin transaction and we are proud that we have repaid within a year the credit we withdrew to finance the acquisition,” said Arvind Utchanah, Chief Financial Officer of Knight. “The repayment which was made within a year was funded by the strong cash flow generated by our business in Canada and Latin America. We appreciate the

MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) - This press release is disseminated by Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. ("Crescita"). Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. Prior to the closing of the Arrangement, Knight had control over 1,935,489 Shares representing approximately 10.4% of the issued and outstanding Shares of Crescita. After closing of the Arrangement, Knight no longer holds any Shares, has ceased to be an insider

MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the Jefferies 2026 Healthcare Conference on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at www.knighttx.com . About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedar.com . Forward-Looking Statement This document contains

MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE ® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. 1 “Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical evidence and a novel mechanism of action. Its availability represents meaningful progress for patients who have not achieved adequate platelet responses with existing treatments, offering renewed confidence in our ability to tailor care to individual disease needs,” said Dr. Luis Meillón,

MONTREAL, May 12, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026 at 9:00 am ET at the InterContinental New York Barclay hotel in New York City. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.knighttx.com or www.sedarplus.ca . Forward-Looking Statement This

MONTREAL, May 08, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., received regulatory approval from ANVISA for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. 1 "Fostamatinib is an effective and well-tolerated new treatment option that addresses an unmet need in Brazil for ITP patients who have had an insufficient response to their treatment and remain at risk of bleeding,” said Dr. Ana Clara Kneese Nascimento, Professor at the Faculty of Medical Sciences of Santa Casa de São Paulo and hematologist responsible for the Platelet Outpatient Clinic of Santa Casa de São Paulo. “We are excited to receive the approval of TAVALISSE in Brazil. The approval of TAVALISSE not only provides a new treatment option with a

Increased 2026 revenue guidance from $510 million to $525 million Achieved record-high quarterly revenues, Adjusted EBITDA 1 and Adjusted EBITDA per share 1 since inception MONTREAL, May 07, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) pharmaceutical company, today reported financial results for its first quarter ended March 31, 2026. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q1-26 Highlights Financial Results - IFRS Revenues were $148,439, an increase of $60,363 or 69% over the same period in prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo portfolios, the growth of our promoted products, and the purchasing patterns of certain products including Ambisome ® deliveries to the MOH. Gross margin was $69,109 or 47% of revenues compared to $34,866 or 40% of revenues

MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal, Quebec ("Meeting"). Election of Directors Each director nominee listed in the Management Information Circular dated April 3, 2026 ("Circular") was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows: DIRECTOR NOMINEE OUTCOME VOTES FOR % FOR VOTES AGAINST % AGAINST Jonathan Ross Goodman Elected 67,561,253 95.00% 3,556,866 5.00% James C. Gale Elected 70,354,667 98.93% 763,452 1.07% Samira Sakhia Elected 70,961,675 99.78% 156,444 0.22% Robert N. Lande Elected 70,849,287 99.62% 268,832 0.38% Michael J. Tremblay Elected 69,898,922 98.29% 1,219,197 1.71% Nicolás Sujoy Elected 70,851,887 99.63% 266,232

MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on Thursday, May 7, 2026 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date : Thursday, May 7, 2026 Time : 8:30 a.m. ET Telephone : Toll Free: 1-888-699-1199 or International 1-416-945-7677 Webcast : www.knighttx.com or Webcast This is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay : An archived replay will be available for 30 days at www.knighttx.com . About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries

MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 21, 2026, at 2:00 p.m. ET at the Metro Toronto Convention Centre (North Building) in Toronto. A copy of the presentation will be available at www.knighttx.com . About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the

MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized on two of The Globe and Mail’s Report on Business magazine’s 2026 national benchmarks: Canada’s Top Growing Women-Led Companies, now in its second year, which highlights Canadian women-led businesses; and Women Lead Here, now in its seventh year, which identifies Canadian public companies demonstrating industry leading levels of executive gender diversity. “Being recognized in both Canada’s Top Growing Women-Led Companies and Women Lead Here is a meaningful milestone for Knight,” said Samira Sakhia, President and Chief Executive Officer of Knight. “This is our first year being named among Canada’s Top Growing Women-Led Companies, a reflection of our sustained growth and the entrepreneurial spirit that drives our organization. In addition, with the continued acknowledgment and progress in advancing gender diversity in leadership,

MONTREAL, March 23, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX:GUD) (" Knight " or the " Company "), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the " TSX ") to amend the Company’s previously announced Notice of Intention to Make a Normal Course Issuer Bid (" NCIB ") to increase the maximum number of common shares (the “ Common Shares ”) that it intends to repurchase for cancellation during the 12-month period ending August 21, 2026, from 3,000,000 Common Shares to 6,190,493 Common Shares, representing approximately 10% of the public float of Common Shares as at August 8, 2025. All other terms and conditions of the NCIB remain unchanged. The Common Shares may be purchased for cancellation through the facilities of the TSX or through alternative Canadian trading systems at times and in numbers to be determined by the Company. During the period from August 22, 2025 to March 19, 2026 inclusively, the

Delivered record-high revenues, Adjusted EBITDA 1 , Adjusted EBITDA per shar e 1 since inception Generated record high cash flow from operations since inception Provides 2026 revenues guidance of $490 million to $510 million and adjusted EBITDA 1 of approximately 15% MONTREAL, March 19, 2026 (GLOBE NEWSWIRE) - Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2025 Highlights Financial results Revenues were $450,088, an increase of $78,784 or 21% over the prior year. The increase was primarily driven by the incremental revenues from the Paladin and Sumitomo Transactions and the growth of our key promoted products, partly offset by declines in our mature and branded generic products,